Rozanolixizumab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 84 publications
Opposing effects of efgartigimod and rozanolixizumab on serum albumin levels in patients with generalized myasthenia gravis.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: February 17, 2026
Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition.
Journal: American journal of therapeutics
Published: January 08, 2026
Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis.
Journal: Journal of neurology
Published: January 06, 2026
Body weight distribution of US patients with myasthenia gravis.
Journal: Journal of medical economics
Published: December 21, 2025
Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis.
Journal: Advances in therapy
Published: December 16, 2025
Depletion and recovery of IgG following treatment with Rozanoliximab and Imlifidase in pigtail macaques.
Journal: bioRxiv : the preprint server for biology
Published: November 26, 2025
Pharmacovigilance analysis of FcRn antagonists in the treatment of myasthenia gravis: A disproportionality analysis based on the FAERS database.
Journal: Human vaccines & immunotherapeutics
Published: November 13, 2025
Pharmacological and speech-language pathology management of dysphagia in patients with myasthenia gravis.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: November 10, 2025
Rozanolixizumab as rescue therapy in triple-seronegative refractory generalized myasthenia gravis.
Journal: Immunological medicine
Published: November 10, 2025
Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis.
Journal: Advances in therapy
Published: October 24, 2025
Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape.
Journal: Expert opinion on emerging drugs
Published: September 23, 2025
Therapeutic approach to myasthenia gravis treatment in the era of new biologics - review of existing and upcoming therapies.
Journal: Neurologia i neurochirurgia polska
Published: September 02, 2025
Last Updated: 04/28/2026